Evaluation of accuracy of one-step nucleic acid amplification (OSNA) in diagnosis of lymph node metastases of papillary thyroid carcinoma. Diagnostic study.
Cervical lymphectomy
Lymph node metastases
One-step nucleic acid amplification (OSNA)
Papillary thyroid carcinoma
Real-time PCR
Journal
Annals of medicine and surgery (2012)
ISSN: 2049-0801
Titre abrégé: Ann Med Surg (Lond)
Pays: England
ID NLM: 101616869
Informations de publication
Date de publication:
Oct 2019
Oct 2019
Historique:
received:
03
06
2019
revised:
13
08
2019
accepted:
17
08
2019
entrez:
6
9
2019
pubmed:
6
9
2019
medline:
6
9
2019
Statut:
epublish
Résumé
The incidence of node metastases in papillary thyroid carcinoma (PTC) is high, ranging from 20% to 90%. Prophylactic central lymph node compartment dissection (CLND), suggested from the latest guidelines for high-risk tumors, meets resistance due to the high incidence of postoperative complications. Recently, new molecular biologic techniques, such as One Step Nucleic Acid Amplification (OSNA), have spread widely, allowing to quickly isolate, amplify and quantify mRNA encoding for proteins selectively present in neoplastic cells, as Cytokeratine-19. The aim of this study is to evaluate the application of OSNA to intraoperative diagnosis of node metastases of PTC. We included in the study patients with preoperative diagnosis of PTC; from each patient one or more lymph nodes were collected. To assess OSNA accuracy, each lymph node was divided into two halves: the first one was analysed with histopathological and immunohistochemical examination, whereas the second was studied with OSNA. Twenty-six lymph nodes from 13 patients were included in the study. Overall, OSNA sensitivity was 87.5%, specificity 94.4%, positive predictive value 87.5%, negative predictive value 94.4% and accuracy 92.8%. OSNA is effective in detecting lymph node metastases of PTC. Considering the high risk of complications in CLND, and the uncertain prognostic value of lymph node metastases of PTC, OSNA seems to be a promising tool to identify intraoperatively patients who may benefit from CLND.
Sections du résumé
BACKGROUND
BACKGROUND
The incidence of node metastases in papillary thyroid carcinoma (PTC) is high, ranging from 20% to 90%. Prophylactic central lymph node compartment dissection (CLND), suggested from the latest guidelines for high-risk tumors, meets resistance due to the high incidence of postoperative complications. Recently, new molecular biologic techniques, such as One Step Nucleic Acid Amplification (OSNA), have spread widely, allowing to quickly isolate, amplify and quantify mRNA encoding for proteins selectively present in neoplastic cells, as Cytokeratine-19. The aim of this study is to evaluate the application of OSNA to intraoperative diagnosis of node metastases of PTC.
METHODS
METHODS
We included in the study patients with preoperative diagnosis of PTC; from each patient one or more lymph nodes were collected. To assess OSNA accuracy, each lymph node was divided into two halves: the first one was analysed with histopathological and immunohistochemical examination, whereas the second was studied with OSNA.
RESULTS
RESULTS
Twenty-six lymph nodes from 13 patients were included in the study. Overall, OSNA sensitivity was 87.5%, specificity 94.4%, positive predictive value 87.5%, negative predictive value 94.4% and accuracy 92.8%.
DISCUSSION AND CONCLUSION
CONCLUSIONS
OSNA is effective in detecting lymph node metastases of PTC. Considering the high risk of complications in CLND, and the uncertain prognostic value of lymph node metastases of PTC, OSNA seems to be a promising tool to identify intraoperatively patients who may benefit from CLND.
Identifiants
pubmed: 31485327
doi: 10.1016/j.amsu.2019.08.006
pii: S2049-0801(19)30116-5
pmc: PMC6717061
doi:
Types de publication
Journal Article
Langues
eng
Pagination
17-22Références
Minerva Chir. 2007 Oct;62(5):383-93
pubmed: 17947949
World J Surg Oncol. 2014 May 20;12:152
pubmed: 24885654
Am Surg. 2003 Mar;69(3):191-6; discussion 196-7
pubmed: 12678473
Curr Opin Oncol. 2006 Jan;18(1):30-5
pubmed: 16357561
Otolaryngol Head Neck Surg. 2003 Jan;128(1):115-23
pubmed: 12574769
Clin Endocrinol (Oxf). 2014 Nov;81(5):754-61
pubmed: 24862564
Surg Oncol. 2002 Nov;11(3):137-42
pubmed: 12356509
Clin Cancer Res. 2007 Aug 15;13(16):4807-16
pubmed: 17699859
Arch Otolaryngol Head Neck Surg. 2002 Jul;128(7):825-8
pubmed: 12117344
Cancer. 2012 Dec 15;118(24):6039-45
pubmed: 22684906
Laryngoscope. 2009 Jun;119(6):1135-9
pubmed: 19358241
Surgery. 2014 Jun;155(6):998-1005
pubmed: 24856120
Int J Cancer. 2008 Jun 1;122(11):2562-7
pubmed: 18324628
Gynecol Oncol. 2016 Oct;143(1):54-59
pubmed: 27498395
Arch Med Sci. 2017 Oct;13(6):1416-1426
pubmed: 29181073
Int J Surg Oncol. 2013;2013:625193
pubmed: 24282633
Histopathology. 2002 May;40(5):403-39
pubmed: 12010363
Thyroid. 2012 Sep;22(9):911-7
pubmed: 22827494
Endocr Pract. 2000 Nov-Dec;6(6):469-76
pubmed: 11155222
Cancer. 2011 Oct 1;117(19):4365-74
pubmed: 21437889
Surgery. 2009 May;145(5):514-8
pubmed: 19375610
Thyroid. 2014 Aug;24(8):1282-8
pubmed: 24787362
J Surg Oncol. 2009 Mar 15;99(4):186-8
pubmed: 19170045
Br J Cancer. 2017 Oct 10;117(8):1185-1191
pubmed: 28797030
Hum Pathol. 2016 Feb;48:132-41
pubmed: 26614398
Br J Cancer. 2013 Sep 17;109(6):1693-8
pubmed: 24002597
Cancer Control. 2000 May-Jun;7(3):240-5
pubmed: 10832110
Eur J Surg Oncol. 2017 Jan;43(1):126-132
pubmed: 27780677
Surgery. 2006 Dec;140(6):1000-5; discussion 1005-7
pubmed: 17188149
Lung Cancer. 2016 Jul;97:1-7
pubmed: 27237020
Int J Clin Exp Pathol. 2013;6(3):510-5
pubmed: 23412848
Gastric Cancer. 2014 Apr;17(2):273-80
pubmed: 23743877
J Invest Surg. 2015 Jun;28(3):153-9
pubmed: 25536089
Thyroid. 2016 Jan;26(1):1-133
pubmed: 26462967
Surgery. 2013 Dec;154(6):1146-7
pubmed: 24238040
Br J Surg. 2013 Feb;100(3):410-8
pubmed: 23188784
Breast Cancer. 2015 Mar;22(2):135-40
pubmed: 23515947
Eur J Surg. 2000 Jan;166(1):29-33
pubmed: 10688213
Ann Surg Oncol. 2013 Jul;20(7):2285-9
pubmed: 23417435